病例报告：一名乳腺小细胞癌患者对萨库珠单抗戈维替康抑制 TROP2 的异常反应。

IF 4.3 2区医学 Q2 ONCOLOGY

Therapeutic Advances in Medical Oncology Pub Date : 2025-02-26 eCollection Date: 2025-01-01 DOI:10.1177/17588359251322003

Kasey C Fitzsimmons, Michelle A Fajardo, Zorawar Noor

{"title":"病例报告：一名乳腺小细胞癌患者对萨库珠单抗戈维替康抑制 TROP2 的异常反应。","authors":"Kasey C Fitzsimmons, Michelle A Fajardo, Zorawar Noor","doi":"10.1177/17588359251322003","DOIUrl":null,"url":null,"abstract":"We present a case report of a patient with metastatic small cell neuroendocrine carcinoma of the breast (SCNCB), a high-grade neuroendocrine triple-negative breast cancer, who achieved a complete response after two cycles of sacituzumab govitecan-hziy (SG) (Trodelvy) as third-line systemic therapy. She originally presented with estrogen receptor-positive disease, and we were able to clearly demonstrate transformation into triple-negative SCNCB via serial tissue biopsies. This is the first reported case of SG for SCNCB, and it shows an outstanding response in a patient who had undergone prior systemic therapies. Clinical trials are needed to address the potential role of TROP2 inhibition and the use of SG as a therapy for SCNCB.","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251322003"},"PeriodicalIF":4.3000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866389/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report.\",\"authors\":\"Kasey C Fitzsimmons, Michelle A Fajardo, Zorawar Noor\",\"doi\":\"10.1177/17588359251322003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We present a case report of a patient with metastatic small cell neuroendocrine carcinoma of the breast (SCNCB), a high-grade neuroendocrine triple-negative breast cancer, who achieved a complete response after two cycles of sacituzumab govitecan-hziy (SG) (Trodelvy) as third-line systemic therapy. She originally presented with estrogen receptor-positive disease, and we were able to clearly demonstrate transformation into triple-negative SCNCB via serial tissue biopsies. This is the first reported case of SG for SCNCB, and it shows an outstanding response in a patient who had undergone prior systemic therapies. Clinical trials are needed to address the potential role of TROP2 inhibition and the use of SG as a therapy for SCNCB.\",\"PeriodicalId\":23053,\"journal\":{\"name\":\"Therapeutic Advances in Medical Oncology\",\"volume\":\"17 \",\"pages\":\"17588359251322003\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866389/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17588359251322003\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359251322003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们报告了一例转移性乳腺小细胞神经内分泌癌（SCNCB）（一种高级别神经内分泌三阴性乳腺癌）患者的病例，该患者在接受了两个周期的sacituzumab govitecan-hziy (SG) (Trodelvy)三线系统治疗后获得了完全应答。她最初表现为雌激素受体阳性疾病，通过连续组织活检，我们能够清楚地证明她已转变为三阴性 SCNCB。这是 SG 治疗 SCNCB 的首个报道病例，它显示了曾接受过全身治疗的患者的出色反应。目前还需要进行临床试验，以确定 TROP2 抑制剂的潜在作用以及将 SG 用作 SCNCB 的疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report.

We present a case report of a patient with metastatic small cell neuroendocrine carcinoma of the breast (SCNCB), a high-grade neuroendocrine triple-negative breast cancer, who achieved a complete response after two cycles of sacituzumab govitecan-hziy (SG) (Trodelvy) as third-line systemic therapy. She originally presented with estrogen receptor-positive disease, and we were able to clearly demonstrate transformation into triple-negative SCNCB via serial tissue biopsies. This is the first reported case of SG for SCNCB, and it shows an outstanding response in a patient who had undergone prior systemic therapies. Clinical trials are needed to address the potential role of TROP2 inhibition and the use of SG as a therapy for SCNCB.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Therapeutic Advances in Medical Oncology ONCOLOGY-

CiteScore

8.20

自引率

2.00%

发文量

160

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).